Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in the Cancer Care Continuum and Mental Health segments which offset a decline in Prenatal Health. The company reaffirmed its full-year 2026 guidance for revenue of $860-$880 million and adjusted EBITDA of $37-$49 million. Strategic milestones included the FDA approval of MyChoice CDx as a companion diagnostic for Zejula in advanced ovarian cancer and the launch of the Precise MRD assay.
Key figures
- Revenue
- $200.4 million
- Guidance
- FY 2026 revenue $860 - $880 million; Adjusted EBITDA $37 - $49 million
- Revenue Yoy
- 2%
- Test volume
- 385000
- Gross margin
- 68.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.